Financing and going-concern risk
The company has limited revenue and relies on external capital to fund operations.
- Scope
- Working capital and development funding
- Materiality
- high
Vivos Inc
Vivos Inc. is a U.S.-based radiation oncology medical device company focused on yttrium-90 (Y-90) precision radionuclide therapy technologies for treating non-resectable tumors. Its core platform includes RadioGel™ and related brachytherapy and isotope-based products developed for use in human and animal cancer treatment.
−4 628,1 %
−87,4 %
−4 483,9 %
+1 268,9 %
14.00
13.52
| % | |
|---|---|
| Precision radionuclide therapy devices | 55% Y-90 based devices and therapies designed to deliver radiation to non-resectable tumors. |
| Animal therapy procedures | 35% IsoPet® treatments administered through veterinary and clinic settings. |
| Research and development services | 10% Development work on new isotope technologies and future cancer applications. |
The company sells into oncology and veterinary treatment settings that use isotope-based therapies for tumors and other...
- Veterinary clinics and animal therapy centersprimary
Buy or administer IsoPet® procedures for animal tumor treatment and related oncology care.
- Human oncology clinics and hospitalsprimary
Potential future buyers of RadioGel™ and other precision radionuclide therapies for non-resectable tumors.
- Clinical research and regulatory partnerssecondary
Support studies, approvals, and evidence generation needed for broader commercialization.
- Manufacturing and commercialization partnerssecondary
Provide outsourced production, sales, distribution, and licensing capabilities.
Vivos is headquartered in Washington State in the United States, and its current commercial activity has been...
- •Headquartered in Kennewick, Washington
- •Current focus has been the Northwestern United States
- •Animal therapy marketing has expanded to other U.S. regions
- •Future commercialization is intended to extend outside the U.S.
- •International growth depends on approvals and licensing partners
Vivos’ strategy centers on advancing regulatory approval for its Y-90 precision radionuclide therapy platform and...
01
Secure regulatory clarity and approvalsshort-term
FDA classification and approval timing determine the path to human commercialization.
02
Build recurring clinical usagemedium-term
Broader clinic adoption is needed to scale IsoPet® and future therapy revenue.
03
Establish commercialization partnersmedium-term
Third-party manufacturing and licensing reduce the need for a large internal sales force.
The business depends on regulatory outcomes, clinical evidence, and the ability to fund development until...
Regulatory approval risk
Commercialization depends on FDA classification and possible additional studies.
- Scope
- RadioGel™ and other precision radionuclide therapies
- Materiality
- high
Commercialization execution risk
Success depends on third-party manufacturing, sales, distribution, and licensing.
- Scope
- U.S. and international rollout
- Materiality
- high
Clinical adoption risk
Hospitals and clinics may adopt the therapy slowly without strong evidence and approvals.
- Scope
- Human oncology and veterinary markets
- Materiality
- medium
Revenue recognition
Can create quarter-to-quarter volatility in reported sales
Inventory and cost of goods sold
Can shift gross margin and cost timing across periods
Stock-based compensation
Raises reported operating costs without cash outflow
Going-concern assessment
Affects disclosure and investor assessment of solvency risk
: 29.4.2026